Go here to see the original:
Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference
Related Post
- Sana Biotechnology Announces Fast Track Designation for SC291 in Relapsed/Refractory Systemic Lupus Erythematosus - December 3rd, 2024
- Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024 - December 3rd, 2024
- OSE Immunotherapeutics Strengthens Leadership and Executive Committee - December 3rd, 2024
- Foundation Fighting Blindness Partners with University of Colorado Anschutz Medical Campus and Other Leading Institutions to Secure Up to $46 Million... - December 3rd, 2024
- Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms - December 3rd, 2024
- Vaxart Completes Enrollment of Sentinel Cohort in Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate - December 3rd, 2024
- Optinose to Present at the Piper Sandler 36th Annual Healthcare Conference - December 3rd, 2024
- vTv Therapeutics to Participate in 7th Annual Evercore HealthCONx Conference - December 3rd, 2024
- Certara Showcases 2024 Research Wins With Over 100 Papers Published - December 3rd, 2024
- Capricor Therapeutics to Present at Upcoming Investor Conferences - December 3rd, 2024
- NKGen Biotech Selected as Stalking Horse Bidder for NKMax - December 3rd, 2024
- Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma - December 3rd, 2024
- Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2024 - December 3rd, 2024
- Bionomics Reminds Shareholders to Cast their Vote for Re-Domiciliation from Australia to the United States - December 3rd, 2024
- Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease... - December 3rd, 2024
- Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q... - December 3rd, 2024
- Rakovina Therapeutics Increases Private Placement Offering to $3.0 Million - December 3rd, 2024
- Revascor Improves Survival and Reduces Major Morbidity in High-Risk Ischemic Heart Failure Patients With Inflammation - December 3rd, 2024
- Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq - December 3rd, 2024
- Prelude Therapeutics to Participate in Citizens JMP Securities Hematology and Oncology Summit - December 1st, 2024
- KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference - December 1st, 2024
- Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - December 1st, 2024
- Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference - December 1st, 2024
- Apyx Medical Corporation to Participate in the Piper Sandler 36th Annual Healthcare Conference - December 1st, 2024
- Radiopharm Achieves Nasdaq Listing of American Depositary Shares - December 1st, 2024
- Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities and Persons Closely Associated - December 1st, 2024
- Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management - December 1st, 2024
- TG Therapeutics to Participate in the Evercore HealthCONx Conference - December 1st, 2024
- Apogee Therapeutics Announces Agenda for Virtual R&D Day - December 1st, 2024
- Mainz Biomed Announces Stock Split - December 1st, 2024
- Fate Therapeutics Announces Leadership Transition - December 1st, 2024
- Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 1st, 2024
- TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split - December 1st, 2024
- Rakovina Therapeutics Announces 2024 Q3 Financial Results and Provides Corporate Update - December 1st, 2024
- Immuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference - November 29th, 2024
- Recce Pharmaceuticals Granted Australia Patent for RECCE® Anti-Infectives - November 29th, 2024
- Kane Biotech Announces Change in US Distribution Partner for revyve™ Antimicrobial Wound Gel - November 29th, 2024
- CytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - November 29th, 2024
- SELLAS Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers - November 29th, 2024
- PHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy area - November 29th, 2024
- Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference - November 29th, 2024
- Windtree Therapeutics Reports Third Quarter 2024 Financial Results and Provides Key Business Updates - November 29th, 2024
- Coherus Management to Participate in the 2024 Citi Global Healthcare Conference - November 29th, 2024
- Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024 - November 29th, 2024
- Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq - November 29th, 2024
- QIAGEN launches novel tools for customizing digital PCR assays and NGS panels for microbial analysis - November 29th, 2024
- Sensei Biotherapeutics to Participate in Citi’s 2024 Global Healthcare Conference - November 29th, 2024
- Celularity Inc. Announces Receipt of Nasdaq Notification - November 29th, 2024
- Applied Therapeutics Receives Complete Response Letter from U.S. FDA Regarding New Drug Application for Govorestat for Classic Galactosemia - November 29th, 2024
- Rakovina Therapeutics Announces Private Placement Offering - November 29th, 2024
- MEDSIR, Featured Company at the Shanghai International Medical Oncology Symposium (7th SIMOS) - November 29th, 2024
- Kane Biotech Announces Third Quarter 2024 Financial Results - November 29th, 2024
- HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms - November 29th, 2024
- Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million - November 29th, 2024
- Lexicon Announces Completion of Enrollment in Phase 2B PROGRESS Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) - November 26th, 2024
- 35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity - November 26th, 2024
- Helio Genomics Presented CLiMB Trial Data Evaluating HelioLiver for Detecting Early-Stage HCC and Methylation Model Score for Assessing Prognosis at... - November 26th, 2024
- Medigene AG Announces Refocus of Corporate Strategy and Organizational Realignment - November 26th, 2024
- Renexxion Ireland Ltd. Announces Issuance of Fifth New U.S. Patent Covering Novel Crystal Isoform of Naronapride - November 26th, 2024
- Praxis Precision Medicines to Showcase Updates from Largest Epilepsy Pipeline of Precision Epilepsy Programs at the 2024 American Epilepsy Society... - November 26th, 2024
- Aura Biosciences to Participate in the 7th Annual Evercore ISI HealthCONx Conference - November 26th, 2024
- Aligos Therapeutics to Present at Investor Conferences in December - November 26th, 2024
- Cabaletta Bio to Participate in Upcoming Investor Conferences in December - November 26th, 2024
- Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy - November 26th, 2024
- Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome - November 26th, 2024
- Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results - November 26th, 2024
- CorMedix Inc. Supports CMS Policy Updates Regarding Access to Innovative Drug Products - November 26th, 2024
- Gelteq Announces 400,000 Units Enter into Production in November 2024 - November 26th, 2024
- Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders - November 26th, 2024
- Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer... - November 26th, 2024
- Wave Life Sciences to Present at Upcoming Investor Conferences - November 26th, 2024
- Stem Cells, Superstars, And Supershow: WWE Superstar Elias Set to Face Off at WrestleCade SuperShow 2024 This Weekend - November 26th, 2024
- Umoja Biopharma to Present at the 7th Annual Evercore ISI HealthCONx Conference - November 26th, 2024
- Valneva Submits Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to the U.S. FDA - November 26th, 2024
- Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors - November 25th, 2024
- GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) - November 25th, 2024
- Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to... - November 25th, 2024
- Vilya Announces Exclusive License Agreement of RFdiffusion-based Generative Model from the University of Washington for the Design of Macrocyclic... - November 25th, 2024
- Chromocell Announces Name Change to “Channel Therapeutics Corporation” and Provides Therapeutic Program Updates - November 25th, 2024
- Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting - November 25th, 2024
Recent Comments